Info
PI3K-mTOR in Cancer and Cancer Therapy / / edited by Nandini Dey, Pradip De, Brian Leyland-Jones
| PI3K-mTOR in Cancer and Cancer Therapy / / edited by Nandini Dey, Pradip De, Brian Leyland-Jones |
| Edizione | [1st ed. 2016.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Humana, , 2016 |
| Descrizione fisica | 1 online resource (XXIV, 294 p. 31 illus. in color.) |
| Disciplina | 616.994071 |
| Collana | Cancer Drug Discovery and Development |
| Soggetto topico |
Cancer - Research
Molecular biology Drug resistance Cancer Research Molecular Medicine Drug Resistance |
| ISBN | 3-319-34211-8 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | PI3K-Akt-mTOR Signaling in Cancer and Cancer Therapeutics -- Part 1: PI3K-mTOR Pathway in Cancers -- The mTOR Complexes in Cancer Cell Metabolism -- PI3K-AKT-mTOR Pathway Co-operates with the DNA Damage Repair Pathway: Carcinogenesis in Triple Negative Breast Cancers and Beyond -- The AKT-mTOR Signaling Pathway for Drug Response Prediction and Prognostic Signatures -- Resistance to PI3K Pathway Inhibition -- Part 2: PI3K-mTOR Pathway in Cancer Medicine -- Combination Therapies Targeting the PI3K/AKT/mTOR Pathways -- Phospho-Inositol-3-Kinase Activity and Dysregulation in Pediatric Leukemia and Lymphoma -- HER2 Signaling Network in Advanced Breast Cancer: Opportunities for Combination Therapies -- The PI3K-mTOR Pathway in Prostate Cancer: Biological Significance and Therapeutic Opportunities. |
| Record Nr. | UNINA-9910254558503321 |
| Cham : , : Springer International Publishing : , : Imprint : Humana, , 2016 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Precision Medicine in Solid Tumors
| Precision Medicine in Solid Tumors |
| Autore | Dey Nandini |
| Descrizione fisica | 1 online resource (304 p.) |
| Soggetto topico |
Medicine and Nursing
Oncology |
| Soggetto non controllato |
adjuvant chemotherapy
anaplastic lymphoma receptor tyrosine kinase breast cancer cancer cancer-associated fibroblasts cfDNA chemotherapy circulating free DNA clinical guideline clonality classification comprehensive genomic profiling CTC ctDNA DDR genes Decision tree digital enrichment driver mutation EGFR mutation EGFR-TKI electronic records epidermal growth factor receptor extent of resection gene panel sequencing glioblastoma prognosis HNSCC immune checkpoint inhibitors immunocytochemistry immunotherapy intratumor heterogeneity laboratory-friendly liquid biopsy molecular barcoding molecular genotyping multiple biopsies n/a new drug development next-generation sequencing next-generation sequencing (NGS) NGS non-small cell lung cancer open data osimertinib outcome overall survival parallel double-detection PARP inhibitors PD-L1 pediatric tumors personalized precision oncology precision medicine presumed germline findings random forest regulatory reform resistance screening sequencing smoking solid cancer strategic therapeutic intervention targeted therapy tDNA thymoma TMB TNBC subtypes triple-negative breast cancer (TNBC) tumor evolution tumor mutational burden tumor profiling test tyrosine kinase inhibitor universal health-care system whole-exome sequencing |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910595078103321 |
Dey Nandini
|
||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||